---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-075126"
form_type: "8-K"
ticker: "NNDM"
cik: "0001643303"
company_name: "Nano Dimension Ltd."
filed_at: "2026-06-17T20:05:32+00:00"
generated_at: "2026-06-17T20:15:25.372373+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nano Dimension provides update on proposed Infinite Epigenetics acquisition, values company at net cash plus 20% premium

## Summary
- Infinite Epigenetics is a commercial diagnostics platform with CLIA-certified lab, >120K samples, and >7,500 healthcare providers.
- Deal values Nano at net cash plus 20% premium; capital to accelerate commercialization and biological AI platform development.
- Nano responds to Murchinson Ltd. criticisms, highlighting board's rigorous review and alignment with shareholder interests.
- Infinite's AI platform uses proprietary DNA methylation data (one of world's largest private datasets), targeting >$90B chronic disease market.
- No transaction-driven compensation for Nano board; shareholders will vote on definitive agreement once finalized.

## SEC filing metadata
- accession: 0001104659-26-075126
- form_type: 8-K
- ticker: NNDM
- cik: 0001643303
- company_name: Nano Dimension Ltd.
- filed_at: 2026-06-17T20:05:32+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1643303/000110465926075126/0001104659-26-075126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1643303/000110465926075126/tm2618166d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-075126
- JSON: https://secwatch.observer/filing/0001104659-26-075126.json
- Plain text: https://secwatch.observer/filing/0001104659-26-075126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.